Company intelligence / Profile preview

Surgical Innovation Associates

Chicago, Illinois, USAproducts.integralife.com ↗

Ownership: Private
Employees: ~37
Development stage: Other

Overview

DuraSorb® has been commercially available since ~2020 with strong revenue growth. A pivotal IDE study was initiated to assess safety and effectiveness of DuraSorb® mesh specifically for prosthetic breast reconstruction. The product has both FDA clearance and CE Mark approval, supporting its use as a resorbable synthetic matrix in soft tissue reinforcement.

Therapeutic areas: RheumatologyWomen's HealthOther
Modalities: DeviceBiologic
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Surgical Innovation Associates.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surgical Innovation Associates.

Explore the full profile